Evidence map›Paper›PMID 42712410›Full record

ReviewFrontiers in pharmacology2026

Therapeutic potential and molecular mechanisms of citrus flavonoids in hepatocellular carcinoma.

Xiaoyan Zhu, Tao Zhang, Ting Gu, Hai Su, Yanyan Ren, Tong Cui

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaoyan ZhuKaramay Central Hospital, Karamay, Xinjiang, China.
Tao ZhangThe First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Ting GuThe First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Hai SuThe First Jikun Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China.
Yanyan RenKaramay Central Hospital, Karamay, Xinjiang, China.
Tong CuiKaramay Central Hospital, Karamay, Xinjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Citrus-derived flavonoids, particularly naringenin, hesperidin, and hesperetin, have emerged as promising bioactive compounds with potential therapeutic relevance in hepatocellular carcinoma (HCC). This review provides a focused synthesis of current preclinical evidence regarding their anticancer properties and underlying molecular mechanisms in experimental HCC models. These flavonoids exert broad anticancer effects, including inhibition of cell proliferation, induction of apoptosis, reduction of oxidative stress, and suppression of tumor progression and metastasis. These activities are mediated through modulation of key oncogenic signaling pathways, which are critically involved in hepatocarcinogenesis. In addition, citrus flavonoids influence mitochondrial function and cellular redox homeostasis, thereby contributing to programmed cell death and metabolic regulation. Preclinical studies further indicate that these compounds may enhance the efficacy of conventional chemotherapeutic agents, including cisplatin, doxorubicin, and sorafenib, while exhibiting reduced toxicity toward normal cells. Moreover, nanoformulation-based delivery systems have been shown to improve their bioavailability and therapeutic performance in experimental models.

Indexed as

hepatocellular carcinomahesperetinhesperidinmetabolic reprogrammingnaringenintherapeutic potential

Identifiers

PMID42712410
PMCPMC13549875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.